WAVEMAN · COMPANY

TLRY · Tilray Brands, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

TLRY

Name: Tilray Brands, Inc. (TLRY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Tilray Brands, Inc.

PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0001731348

CLUSTER · 3 INSIDERSC-SUITE BUYING · 3☆ WATCH

INSIDER NET · 180D

-$163.7K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

107

13F, latest reported quarter

REVENUE GROWTH

+11.5%

XBRL, annual

NET MARGIN

-13.3%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$163.7K over 180 days

+$69.2K over 90 days

more than 53% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

107 funds added or opened last quarter

more than 68% of Pharma & Biotech

REVENUE

+11.5% year over year

more than 62% of Pharma & Biotech

MARGIN

-13.3% net margin

more than 53% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

107 funds added or opened positions in the latest 13F quarter, of 236 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -63.8%

-63.8%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $163.7K sold by insiders over 180 days, 107 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Tilray Brands, Inc. insiders sold a net $163.7K of stock across 23 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Gendel Mitchell

Global General Counsel

BUY

2026-08-06

2,500.0

$11.1K

Merton Carl A

Chief Financial Officer

BUY

2026-08-04

10,000.0

$46.2K

FALTISCHEK DENISE M

Chief Strategy Officer

BUY

2026-08-03

2,500.0

$11.9K

Hopkinson David G.

Director

SELL

2026-04-21

33,556.0

$232.9K

Gendel Mitchell

Global General Counsel

BUY

2025-07-31

6,000.0

$3.5K

23 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 18 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Tidal Investments LLC

2,498,656.0 sh

$11.2M

SUSQUEHANNA INTERNATIONAL GROUP, LLP

1,021,777.0 sh

$4.6M

MORGAN STANLEY

995,145.0 sh

$4.5M

CITADEL ADVISORS LLC

868,147.0 sh

$3.9M

Point72 Asset Management, L.P.

648,506.0 sh

$2.9M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Amplify Alternative Harvest ETF

$16.4M POSITION · AS OF 2026-03-31

14.2%

AdvisorShares Pure Cannabis ETF

$412.5K POSITION · AS OF 2026-03-31

1.3%

The Free Markets ETF

$172.9K POSITION · AS OF 2026-02-28

1.0%

Sofi Social 50 ETF

$74.3K POSITION · AS OF 2026-02-28

0.2%

Invesco RAFI Developed Markets ex-U.S. Small-Mid ETF

$255.4K POSITION · AS OF 2026-04-30

0.1%

Innovator U.S. Small Cap Managed Floor ETF

$44.9K POSITION · AS OF 2026-04-30

0.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-05	2025-12	2025-05	2024-05
REVENUE	$915.5M	—	$821.3M	$788.9M
GROSS PROFIT	$260.4M	—	$240.6M	$223.4M
OPERATING INCOME	$-63.0M	—	$-2.3B	$-174.7M
NET INCOME	$-121.4M	—	$-2.2B	$-245.0M
EPS (DILUTED)	-1.09	—	-24.56	-3.30
OPERATING CASH FLOW	$-69.1M	—	$-94.6M	$-30.9M
CASH	$226.0M	$221.7M	$221.7M	$228.3M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE